<p>Kestra Medical Technologies, Ltd.（NASDAQ:KMTS - 获取免费报告）的股票在周五下跌了 7.2%，原因是高盛集团将该股票的目标价从 22.00 美元下调至 17.00 美元。高盛集团目前对该股票的评级为中性。Kestra Medical Technologies 的股价最低曾达到 18.05 美元，最后交易价为 17.8650 美元。在交易过程中，约有 82,926 股易手，较平均每日成交量 346,349 股下降了 76%。该股票之前的收盘价为 19.25 美元。</p>
<p>其他分析师也对该股票发布了研究报告。BTIG Research 在周二的研究报告中重申了对 Kestra Medical Technologies 的 “买入” 评级，并设定了 32.00 美元的目标价。Stifel Nicolaus 在 12 月 12 日（周五）的研究报告中设定了 30.00 美元的目标价。Piper Sandler 在 12 月 12 日（周五）的研究报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 30.00 美元，并给予该公司 “超配” 评级。Wells Fargo &amp; Company 在 12 月 12 日（周五）的研究报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 28.00 美元，并给予该公司 “超配” 评级。最后，Weiss Ratings 在 3 月 23 日（周一）的研究报告中重申了对 Kestra Medical Technologies 的 “卖出（d-）” 评级。三位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 27.40 美元。</p>
<p><strong>查看我们最新的 KMTS 股票报告</strong></p>
<h2>Kestra Medical Technologies 的内部活动</h2>
<p>在相关消息中，内部人士 Brian Daniel Webster 在 3 月 17 日（周二）出售了 15,000 股该股票。股票以平均价格 20.27 美元出售，总价值为 304,050.00 美元。交易完成后，该内部人士在公司持有 364,786 股，价值 7,394,212.22 美元。这代表其持股比例下降了 3.95%。该出售在向 SEC 的备案中披露，相关文件可通过此链接获取。内部人士在过去三个月内共出售了价值 1,030,050 美元的 45,000 股公司股票。目前，3.60% 的股票由公司内部人士持有。</p>
<h2>对 Kestra Medical Technologies 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近买入和卖出了该股票的股份。Farther Finance Advisors LLC 在第四季度购买了 Kestra Medical Technologies 的新股份，价值 31,000 美元。Russell Investments Group Ltd.在第四季度将其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.现在持有该公司 1,563 股股票，价值 41,000 美元，此前在该期间又购买了 474 股。China Universal Asset Management Co. Ltd.在第三季度购买了 Kestra Medical Technologies 的新股份，价值约 48,000 美元。BNP Paribas Financial Markets 在第三季度将其在 Kestra Medical Technologies 的股份增加了 148.9%。BNP Paribas Financial Markets 现在持有该公司 2,738 股股票，价值 65,000 美元，此前在上个季度又购买了 1,638 股。最后，Daiwa Securities Group Inc.在第四季度购买了 Kestra Medical Technologies 的新股份，价值约 72,000 美元。</p>
<h2>Kestra Medical Technologies 股票下跌 7.0%</h2>
<p>该公司的 50 日简单移动平均线为 22.79 美元，200 日简单移动平均线为 24.48 美元。该公司的速动比率为 7.32，流动比率为 7.32，债务与股本比率为 0.15。该公司的市值为 10.4 亿美元，市盈率为-4.52。</p>
<p>Kestra Medical Technologies（NASDAQ:KMTS - 获取免费报告）在 3 月 17 日（周二）发布了季度财报。该公司报告季度每股收益为（0.61 美元），低于分析师一致预期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的股本回报率为-65.49%，净利润率为-171.87%。该公司在本季度的收入为 2455 万美元。Kestra Medical Technologies 的季度收入同比增长 62.7%。</p>
<h2>Kestra Medical Technologies 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家商业阶段的可穿戴医疗设备和数字医疗公司，专注于通过直观、智能和互联的监测和治疗干预技术来改善心血管疾病患者的结果。我们开发并商业化了我们的心脏恢复系统平台，这是一个综合且先进的系统，将监测、治疗、数字健康和患者支持服务整合为一个统一的解决方案。我们心脏恢复系统平台的基石是 ASSURE WCD，这是一种下一代可穿戴心脏复律除颤器（“WCD”），用于保护处于突发心脏骤停（“SCA”）高风险的患者，这是一种公共卫生问题，约占美国所有心血管死亡的 50%。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Kestra Medical Technologies 更具吸引力</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kestra Medical Technologies 吗？</h2>
<p>在考虑 Kestra Medical Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kestra Medical Technologies 并不在名单上。</p>
<p>虽然 Kestra Medical Technologies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

KMTS

<p>Kestra Medical Technologies（纳斯达克代码：KMTS）的股价下跌了 7.2%，原因是高盛将其评级下调，并将目标价从 22.00 美元下调至 17.00 美元。该股最低交易价为 18.05 美元，交易量显著下降。其他分析师的评级则各有不同，BTIG Research 维持 “买入” 评级，目标价为 32.00 美元。尽管公司报告的季度每股收益为（0.61 美元），未能达到预期，但其营收同比增长了 62.7%。Kestra 专注于心血管疾病管理的可穿戴医疗设备</p>

<p>Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) were down 7.2% on Friday after The Goldman Sachs Group lowered their price target on the stock from $22.00 to $17.00. The Goldman Sachs Group currently has a neutral rating on the stock. Kestra Medical Technologies traded as low as $18.05 and last traded at $17.8650. Approximately 82,926 shares changed hands during trading, a decline of 76% from the average daily volume of 346,349 shares. The stock had previously closed at $19.25.</p>
<div class="lb-trans"><p>Kestra Medical Technologies, Ltd.（NASDAQ:KMTS - 获取免费报告）的股票在周五下跌了 7.2%，原因是高盛集团将该股票的目标价从 22.00 美元下调至 17.00 美元。高盛集团目前对该股票的评级为中性。Kestra Medical Technologies 的股价最低曾达到 18.05 美元，最后交易价为 17.8650 美元。在交易过程中，约有 82,926 股易手，较平均每日成交量 346,349 股下降了 76%。该股票之前的收盘价为 19.25 美元。</p>
</div><p>Other analysts have also issued research reports about the stock. BTIG Research reiterated a &#34;buy&#34; rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday. Stifel Nicolaus set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Friday, December 12th. Piper Sandler boosted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Wells Fargo &amp; Company boosted their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average price target of $27.40.</p>
<div class="lb-trans"><p>其他分析师也对该股票发布了研究报告。BTIG Research 在周二的研究报告中重申了对 Kestra Medical Technologies 的 “买入” 评级，并设定了 32.00 美元的目标价。Stifel Nicolaus 在 12 月 12 日（周五）的研究报告中设定了 30.00 美元的目标价。Piper Sandler 在 12 月 12 日（周五）的研究报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 30.00 美元，并给予该公司 “超配” 评级。Wells Fargo &amp; Company 在 12 月 12 日（周五）的研究报告中将 Kestra Medical Technologies 的目标价从 27.00 美元上调至 28.00 美元，并给予该公司 “超配” 评级。最后，Weiss Ratings 在 3 月 23 日（周一）的研究报告中重申了对 Kestra Medical Technologies 的 “卖出（d-）” 评级。三位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 27.40 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on KMTS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 KMTS 股票报告</strong></p>
</div><h2>Insider Activity at Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 的内部活动</h2>
</div><p>In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the transaction, the insider owned 364,786 shares in the company, valued at $7,394,212.22. This represents a 3.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 45,000 shares of company stock worth $1,030,050 in the last three months. 3.60% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Brian Daniel Webster 在 3 月 17 日（周二）出售了 15,000 股该股票。股票以平均价格 20.27 美元出售，总价值为 304,050.00 美元。交易完成后，该内部人士在公司持有 364,786 股，价值 7,394,212.22 美元。这代表其持股比例下降了 3.95%。该出售在向 SEC 的备案中披露，相关文件可通过此链接获取。内部人士在过去三个月内共出售了价值 1,030,050 美元的 45,000 股公司股票。目前，3.60% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>对 Kestra Medical Technologies 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at $31,000. Russell Investments Group Ltd. raised its holdings in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after buying an additional 474 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Kestra Medical Technologies during the third quarter valued at about $48,000. BNP Paribas Financial Markets lifted its stake in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock valued at $65,000 after buying an additional 1,638 shares in the last quarter. Finally, Daiwa Securities Group Inc. purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at about $72,000.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买入和卖出了该股票的股份。Farther Finance Advisors LLC 在第四季度购买了 Kestra Medical Technologies 的新股份，价值 31,000 美元。Russell Investments Group Ltd.在第四季度将其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.现在持有该公司 1,563 股股票，价值 41,000 美元，此前在该期间又购买了 474 股。China Universal Asset Management Co. Ltd.在第三季度购买了 Kestra Medical Technologies 的新股份，价值约 48,000 美元。BNP Paribas Financial Markets 在第三季度将其在 Kestra Medical Technologies 的股份增加了 148.9%。BNP Paribas Financial Markets 现在持有该公司 2,738 股股票，价值 65,000 美元，此前在上个季度又购买了 1,638 股。最后，Daiwa Securities Group Inc.在第四季度购买了 Kestra Medical Technologies 的新股份，价值约 72,000 美元。</p>
</div><h2>Kestra Medical Technologies Stock Down 7.0%</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 股票下跌 7.0%</h2>
</div><p>The business's 50 day simple moving average is $22.79 and its 200 day simple moving average is $24.48. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.04 billion and a PE ratio of -4.52.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 22.79 美元，200 日简单移动平均线为 24.48 美元。该公司的速动比率为 7.32，流动比率为 7.32，债务与股本比率为 0.15。该公司的市值为 10.4 亿美元，市盈率为-4.52。</p>
</div><p>Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies's revenue for the quarter was up 62.7% on a year-over-year basis.</p>
<div class="lb-trans"><p>Kestra Medical Technologies（NASDAQ:KMTS - 获取免费报告）在 3 月 17 日（周二）发布了季度财报。该公司报告季度每股收益为（0.61 美元），低于分析师一致预期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的股本回报率为-65.49%，净利润率为-171.87%。该公司在本季度的收入为 2455 万美元。Kestra Medical Technologies 的季度收入同比增长 62.7%。</p>
</div><h2>Kestra Medical Technologies Company Profile</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.</p>
<div class="lb-trans"><p>我们是一家商业阶段的可穿戴医疗设备和数字医疗公司，专注于通过直观、智能和互联的监测和治疗干预技术来改善心血管疾病患者的结果。我们开发并商业化了我们的心脏恢复系统平台，这是一个综合且先进的系统，将监测、治疗、数字健康和患者支持服务整合为一个统一的解决方案。我们心脏恢复系统平台的基石是 ASSURE WCD，这是一种下一代可穿戴心脏复律除颤器（“WCD”），用于保护处于突发心脏骤停（“SCA”）高风险的患者，这是一种公共卫生问题，约占美国所有心血管死亡的 50%。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Kestra Medical Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Kestra Medical Technologies 更具吸引力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kestra Medical Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kestra Medical Technologies 吗？</h2>
</div><p>Before you consider Kestra Medical Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kestra Medical Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kestra Medical Technologies 并不在名单上。</p>
</div><p>While Kestra Medical Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kestra Medical Technologies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kestra Medical Technologies (NASDAQ:KMTS) 的股票价格因分析师的评级下调而下跌了 7.2%